Chemours price target raised to $36 from $35 at RBC Capital

RBC Capital analyst Arun Viswanathan raised the firm’s price target on Chemours to $36 from $35 after its Q1 earnings beat but keeps a Sector Perform rating on the shares. Much of the improvement is expected in the second half of the year, which remains tied to an uncertain global economic environment, the analyst tells investors in a research note. The firm is also reducing its assumed expected 2023 EBITDA multiple to 6.0-times from 6.5-times.